Effect of Infliximab and Adalimumab on Experimental Colitis Following Orally Supplemented Iron. (2nd January 2017)

• Record Type: Journal Article
• Authors: Triantafillidis, John; Vagianos, Costas; Agrogiannis, George; Gikas, Aristofanis; Douvi, Georgia; Syrmos, Nikolaos; Patsouris, Efstratios; Papalois, Apostolos
• Is Part Of: Journal of investigative surgery. Volume 30:Number 1(2017)
• Page Start: 6
• Page End: 12
• Publication Date: 2017-01-02
• Subjects: experimental colitis -- ulcerative colitis -- Crohn's disease -- inflammatory bowel disease -- iron -- anemia -- infliximab -- adalimumab -- biologic agents; Surgery -- Research -- Periodicals; Research; Surgery; Surgical Procedures, Operative; 617.075
• DOI: 10.1080/08941939.2016.1215574
• Languages: English
• ISSNs: 0894-1939

Abstract

ABSTRACT: Background: Orally administered iron can induce colonic inflammation in healthy animals and aggravate experimental colitis. Aim: To investigate the influence of the biologic agents infliximab and adalimumab on the severity of TNBS colitis following orally supplemented iron. Materials-Methods: 204 Wistar rats were allocated into 14 groups. Colitis was induced by TNBS. Iron was administered via a mouth catheter at a dose of 0.027, 0.3, and 3%/kg diet per day, respectively. Infliximab was subcutaneously administered on the 2 nd and 6 th day in a dose of 5 mg/kgBW, while adalimumab was administered on the 2 nd day in a dose of 2 mg/kgBW. On the 8 th day, all animals were euthanatized. Activity of colitis and extent of tissue damage were assessed histologically. Tissue Tumor Necrosis Factor-α (t-TNF-α) and malondialdehyde (t-MDA) were estimated. Results: In normal rats both agents significantly worsen the degree of inflammation induced by moderate or high iron supplementation despite the disappearance of t-TNF-α, and reduction of t-MDA. In the groups of TNBS colitis and moderate or high iron administration, both agents again significantly worsen the degree of inflammation despite the significant reduction in the t-TNF-α and t-MDA. Conclusion: Adalimumab and infliximab do not ameliorate the inflammation in TNBS-induced colitis aggravated by orally administered iron. These findings might be clinically relevant in patients with active IBD under concurrent treatment with biologic agents and per oral iron.